Literature DB >> 34818153

Validated scoring system identifies low-risk syncope patients.

Amanda Kay Lewton1, Laura Elizabeth Morris1.   

Abstract

This study validated the Canadian Syncope Risk Score for predicting 30-day serious outcomes in patients presenting to the ED within 24 hours of syncope.

Entities:  

Mesh：

Year:  2021        PMID： 34818153      PMCID： PMC8619809          DOI： 10.12788/jfp.0309

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  4 in total

1.  2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Win-Kuang Shen; Robert S Sheldon; David G Benditt; Mitchell I Cohen; Daniel E Forman; Zachary D Goldberger; Blair P Grubb; Mohamed H Hamdan; Andrew D Krahn; Mark S Link; Brian Olshansky; Satish R Raj; Roopinder Kaur Sandhu; Dan Sorajja; Benjamin C Sun; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2017-03-09       Impact factor: 24.094

2.  National trends in resource utilization associated with ED visits for syncope.

Authors:  Marc A Probst; Hemal K Kanzaria; Misato Gbedemah; Lynne D Richardson; Benjamin C Sun
Journal:  Am J Emerg Med       Date:  2015-04-24       Impact factor: 2.469

3.  Multicenter Emergency Department Validation of the Canadian Syncope Risk Score.

Authors:  Venkatesh Thiruganasambandamoorthy; Marco L A Sivilotti; Natalie Le Sage; Justin W Yan; Paul Huang; Mona Hegdekar; Eric Mercier; Muhammad Mukarram; Marie-Joe Nemnom; Andrew D McRae; Brian H Rowe; Ian G Stiell; George A Wells; Andrew D Krahn; Monica Taljaard
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

4.  Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope.

Authors:  Venkatesh Thiruganasambandamoorthy; Kenneth Kwong; George A Wells; Marco L A Sivilotti; Muhammad Mukarram; Brian H Rowe; Eddy Lang; Jeffrey J Perry; Robert Sheldon; Ian G Stiell; Monica Taljaard
Journal:  CMAJ       Date:  2016-07-04       Impact factor: 8.262
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.